Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Turkish Towns Provide Genetic Link to Malignant Mesothelioma

June 1, 2001
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 6
Volume 10
Issue 6

CHICAGO-An analysis of a six-generation extended pedigree of 526 people from two small Turkish villages showed that mesothelioma is genetically transmitted, and that building materials containing erionite may be a cofactor.

CHICAGO—An analysis of a six-generation extended pedigree of 526 people from two small Turkish villages showed that mesothelioma is genetically transmitted, and that building materials containing erionite may be a cofactor.

The pedigree analysis of individuals from Karain (population about 600) and Tuzköy (1,400) suggests that mesothelioma is probably transmitted in an autosomal dominant way, Michele Carbone, MD, reported at a conference on malignant mesothelioma hosted by the University of Chicago. [Look for more reports from this meeting next month, including a consensus statement on the role of SV40 in the disease.]

In the villages of Karain and Tuzköy, malignant mesothelioma causes more than 50% of deaths, yet surrounding villages appear unaffected by mesothelioma. This finding prompted researchers to look for the causative agent, asbestos, in the two villages.

Investigators thought they had isolated the causative agent, but subsequently discovered that asbestos was a natural component of the volcanic terrain of this Cappadocian region. Since asbestos was found nearly everywhere in the region, it could not account for the uniquely high incidence of mesotheliomas in these two villages.

Further research implicated erionite, a mineral fiber that had been detected in the lungs of several villagers. In addition, erionite was found to cause mesothelioma tumors in rodents. However, erionite, like asbestos, was also found to be common throughout most villages of this region and thus, by itself, could not account for the high incidence of mesothelioma deaths.

Dr. Carbone, associate professor of pathology, Loyola University Medical Center, Maywood, Illinois, noted that malignant mesothelioma occurred mostly in specific homes where entire families had died from the disease. Residents of the villages referred to these as "the houses of death."

On one visit to Karain, Dr. Carbone observed these houses first-hand (see Figure). As he left one such house, a child immediately began brushing a white powder, presumably containing erionite, from his jacket where it had rubbed against the stone wall of the house.

Local authorities told Dr. Carbone that these "houses of death" contained a greater amount of the causative agent, erionite, even though neighboring houses appeared to have been built at about the same time with what appeared to be the same type of stones.

Subsequent research confirmed the widespread use of erionite-containing stones throughout other Turkish villages in the region, with and without a high incidence of malignant mesothelioma deaths, thus ruling out erionite as the sole causative agent.

Dr. Carbone began investigating the genetic evidence in Turkish villages. Similar familial clusters of mesotheliomas had already been observed in certain Western families, supporting a comparable hypothesis that genetic transmission caused a predisposition in Western countries to asbestos or SV40 carcinogenesis.

Gathering Genetic Data

To study the genetic hypothesis, one investigator from Dr. Carbone’s research team, Iman Roushdy-Hammady, a PhD candidate in medical anthropology, spent 2 years living in these Turkish villages, and several months living in Sweden and Germany to study emigrants who originated from these villages. Mr. Roushdy-Hammady was able to pierce substantial cultural barriers to gathering epidemiologic and genetic data, which were then analyzed by Dr. Carbone’s research team.

Dr. Carbone said that six families were identified in which mesothelioma showed obvious familial clustering. The six families were linked to one large six-generation extended pedigree of 526 individuals. Among these individuals, Dr. Carbone identified 22 affected nuclear families with 87 children of affected parents—41 of these 87 children had developed malignant mesothelioma as adults.

The number of children with mesothelioma, 41 cases, did not differ significantly from the number of cases that would have been predicted from an autosomal dominant pattern of inheritance: 43.5 children (P = .5). This finding suggests that malignant mesothelioma segregates in an autosomal dominant pattern and that erionite might be a cofactor in genetically predisposed individuals, Dr. Carbone said. He hopes that further information will allow linkage analysis to identify those genetic-susceptibility factor(s) that predispose individuals to malignant mesothelioma in Cappadocian villages. "It is possible that the same gene that is genetically mutated in Cappadocia may be the target of asbestos and SV40 carcinogenesis [the causes of mesothelioma seen in developed countries]," he said. Isolation of this putative gene may pave the way to understanding molecular pathogenesis of the disease.

Articles in this issue

ACS and NCCN Issue Cancer Pain Management Guidelines for Patients
Xeloda Approved for Metastatic Colorectal Cancer
Walking Improves Fatigue, Sleep in Breast Cancer Patients
Bezwoda 1985 Breast Cancer Transplant Study Fraudulent
Severity of Hot Flashes Worse in Breast Cancer Survivors
Tamoxifen Prevents BRCA2, But Not BRCA1, Breast Cancer
High TIMP-1 Levels May Promote Prostate Cancer Growth
Barriers to Colorectal Cancer Screening Among Minorities
Epoetin Reduces Need for Red Blood Cell Transfusions
French Researchers Discover How HIV Makes First Contact
‘Virtual Supercomputer’ Program for Cancer Drug Discovery
Agent Orange Linked to AML in Offspring
Turkish Towns Provide Genetic Link to Malignant Mesothelioma
President Allows Implementation of Patient Privacy Rule
Gleevec Is Approved for Chronic Myelogenous Leukemia

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
5 experts are featured in this series
4 experts in this video
2 experts are featured in this series.
4 experts in this video
4 experts in this video
4 experts in this video
2 experts are featured in this series.
Related Content

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Ariana Pelosci
July 25th 2025
Article

Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

Russ Conroy
July 25th 2025
Article

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.


Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.

EC Approves Cabozantinib Monotherapy in Previously Treated pNET/epNET

Tim Cortese
July 25th 2025
Article

Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.

Related Content

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Mirvetuximab Soravtansine Receives Conditional Marketing Authorization in GYN Subtypes

Ariana Pelosci
July 25th 2025
Article

Patients with FRα+, platinum-resistant high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer may now be eligible for mirvetuximab soravtansine in the UK.


Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.

Advancements and Evolving Strategies in Breast Cancer Treatment at IBC East

Heather McArthur, MD, MPH;Erika P. Hamilton, MD;Hope S. Rugo, MD;Paolo Tarantino, MD, PhD
July 21st 2025
Podcast

Leading experts in the breast cancer field highlight the use of CDK4/6 inhibitors, antibody-drug conjugates, and other treatment modalities.


Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.

Personalized Cancer Vaccines May Transform Treatment Options in Kidney Cancer

Roman Fabbricatore
July 25th 2025
Article

Personalized kidney cancer vaccines may help guide immune therapies to more effectively attack cancerous cells while mitigating harm to healthy tissue.


According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.

Taletrectinib Approval Expands Options in Advanced/Metastatic ROS1+ NSCLC

Jorge Nieva, MD
July 14th 2025
Podcast

According to Jorge Nieva, MD, taletrectinib may be a primary frontline therapy option for those with ROS1-positive non–small cell lung cancer.


Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.

Research Consortium Aims to Accelerate Progress in Kidney Cancer Management

Russ Conroy
July 25th 2025
Article

Collaborators in the Kidney Cancer Research Consortium aim to address mechanistic and scientifically driven questions in the kidney cancer field.


Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.

EC Approves Cabozantinib Monotherapy in Previously Treated pNET/epNET

Tim Cortese
July 25th 2025
Article

Results from the phase 3 CABINET trial demonstrated a clear progression-free survival benefit with cabozantinib vs placebo in patients with well-differentiated pNET/epNET.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.